Panaji: Glenmark Pharmaceuticals, announced a price reduction of 27 per cent in FabiFlu, the first oral Favipiravir approved drug in India for the treatment of mild to moderate COVID-19. The new price of FabiFlu is Rs 75 per tab from the earlier Rs 103 per tab.
The company said that, the price reduction has been made possible through benefits gained from higher yields and better scale, as both the API and formulations are made in India.
Glenmark also said that it has commenced a post marketing surveillance study of FabiFlu to closely monitor the efficacy and safety of the drug on 1000 patients prescribed with the oral antiviral, as part of an open label, multicenter, single arm study.
Alok Malik, senior vice president and head, India business, said that, the post marketing surveillance study will help to shed more light on the clinical effectiveness and safety of patients prescribed FabiFlu.
According to Glenmark, the company launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. “We hope that this further price reduction will make it even more accessible for patients across the country,” added Malik.
On June 20, Glenmark received manufacturing and marketing approval from the government for FabiFlu. The manufacturing and marketing approval was granted as part of accelerated approval process, considering the emergency situation of the COVID-19 outbreak in the country. The approval’s restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.